These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

353 related articles for article (PubMed ID: 33879243)

  • 41. Amyloid-β levels and cognitive trajectories in non-demented pTau181-positive subjects without amyloidopathy.
    Oberstein TJ; Schmidt MA; Florvaag A; Haas AL; Siegmann EM; Olm P; Utz J; Spitzer P; Doerfler A; Lewczuk P; Kornhuber J; Maler JM
    Brain; 2022 Nov; 145(11):4032-4041. PubMed ID: 35973034
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cognitive function in very old men does not correlate to biomarkers of Alzheimer's disease.
    Velickaite V; Giedraitis V; Ström K; Alafuzoff I; Zetterberg H; Lannfelt L; Kilander L; Larsson EM; Ingelsson M
    BMC Geriatr; 2017 Sep; 17(1):208. PubMed ID: 28886705
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Additional use of Aβ₄₂/Aβ₄₀ ratio with cerebrospinal fluid biomarkers P-tau and Aβ₄₂ increases the level of evidence of Alzheimer's disease pathophysiological process in routine practice.
    Sauvée M; DidierLaurent G; Latarche C; Escanyé MC; Olivier JL; Malaplate-Armand C
    J Alzheimers Dis; 2014; 41(2):377-86. PubMed ID: 24614902
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Cerebrospinal fluid biomarkers distinguish postmortem-confirmed Alzheimer's disease from other dementias and healthy controls in the OPTIMA cohort.
    Seeburger JL; Holder DJ; Combrinck M; Joachim C; Laterza O; Tanen M; Dallob A; Chappell D; Snyder K; Flynn M; Simon A; Modur V; Potter WZ; Wilcock G; Savage MJ; Smith AD
    J Alzheimers Dis; 2015; 44(2):525-39. PubMed ID: 25391385
    [TBL] [Abstract][Full Text] [Related]  

  • 45. High tau levels in cerebrospinal fluid predict nursing home placement and rapid progression in Alzheimer's disease.
    Degerman Gunnarsson M; Ingelsson M; Blennow K; Basun H; Lannfelt L; Kilander L
    Alzheimers Res Ther; 2016 Jun; 8(1):22. PubMed ID: 27263933
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Prediction of Cognitive Progression in Individuals with Mild Cognitive Impairment Using Radiomics as an Improvement of the ATN System: A Five-Year Follow-Up Study.
    Song R; Wu X; Liu H; Guo D; Tang L; Zhang W; Feng J; Li C
    Korean J Radiol; 2022 Jan; 23(1):89-100. PubMed ID: 34983097
    [TBL] [Abstract][Full Text] [Related]  

  • 47. AD-Related CSF Biomarkers Across Distinct Levels of Cognitive Impairment: Correlations With Global Cognitive State.
    Ibarra R; Radanovic M; Pais MV; Talib LL; Forlenza OV
    J Geriatr Psychiatry Neurol; 2021 Nov; 34(6):659-667. PubMed ID: 32757819
    [TBL] [Abstract][Full Text] [Related]  

  • 48. CSF biomarkers predict rate of cognitive decline in Alzheimer disease.
    Kester MI; van der Vlies AE; Blankenstein MA; Pijnenburg YA; van Elk EJ; Scheltens P; van der Flier WM
    Neurology; 2009 Oct; 73(17):1353-8. PubMed ID: 19858456
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Association of CSF, Plasma, and Imaging Markers of Neurodegeneration With Clinical Progression in People With Subjective Cognitive Decline.
    Ebenau JL; Pelkmans W; Verberk IMW; Verfaillie SCJ; van den Bosch KA; van Leeuwenstijn M; Collij LE; Scheltens P; Prins ND; Barkhof F; van Berckel BNM; Teunissen CE; van der Flier WM
    Neurology; 2022 Mar; 98(13):e1315-e1326. PubMed ID: 35110378
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Influence of plasma matrix metalloproteinase levels on longitudinal changes in Alzheimer's disease (AD) biomarkers and cognitive function in patients with mild cognitive impairment due to AD registered in the Alzheimer's Disease Neuroimaging Initiative database.
    Abe K; Chiba Y; Hattori S; Yoshimi A; Asami T; Katsuse O; Suda A; Hishimoto A;
    J Neurol Sci; 2020 Sep; 416():116989. PubMed ID: 32603972
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Discordant amyloid-β PET and CSF biomarkers and its clinical consequences.
    de Wilde A; Reimand J; Teunissen CE; Zwan M; Windhorst AD; Boellaard R; van der Flier WM; Scheltens P; van Berckel BNM; Bouwman F; Ossenkoppele R
    Alzheimers Res Ther; 2019 Sep; 11(1):78. PubMed ID: 31511058
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Dual-Task Performance and Neurodegeneration: Correlations Between Timed Up-and-Go Dual-Task Test Outcomes and Alzheimer's Disease Cerebrospinal Fluid Biomarkers.
    Åhman HB; Giedraitis V; Cedervall Y; Lennhed B; Berglund L; McKee K; Kilander L; Rosendahl E; Ingelsson M; Åberg AC
    J Alzheimers Dis; 2019; 71(s1):S75-S83. PubMed ID: 31104024
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Cerebro-spinal fluid biomarker levels: phosphorylated tau (T) and total tau (N) as markers for rate of progression in Alzheimer's disease.
    Wattmo C; Blennow K; Hansson O
    BMC Neurol; 2020 Jan; 20(1):10. PubMed ID: 31918679
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cerebrospinal fluid synaptosomal-associated protein 25 is a key player in synaptic degeneration in mild cognitive impairment and Alzheimer's disease.
    Zhang H; Therriault J; Kang MS; Ng KP; Pascoal TA; Rosa-Neto P; Gauthier S;
    Alzheimers Res Ther; 2018 Aug; 10(1):80. PubMed ID: 30115118
    [TBL] [Abstract][Full Text] [Related]  

  • 55. ATN profiles among cognitively normal individuals and longitudinal cognitive outcomes.
    Soldan A; Pettigrew C; Fagan AM; Schindler SE; Moghekar A; Fowler C; Li QX; Collins SJ; Carlsson C; Asthana S; Masters CL; Johnson S; Morris JC; Albert M; Gross AL
    Neurology; 2019 Apr; 92(14):e1567-e1579. PubMed ID: 30842300
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Association of glial and neuronal degeneration markers with Alzheimer's disease cerebrospinal fluid profile and cognitive functions.
    Teitsdottir UD; Jonsdottir MK; Lund SH; Darreh-Shori T; Snaedal J; Petersen PH
    Alzheimers Res Ther; 2020 Aug; 12(1):92. PubMed ID: 32753068
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Association of weight change with cerebrospinal fluid biomarkers and amyloid positron emission tomography in preclinical Alzheimer's disease.
    Grau-Rivera O; Navalpotro-Gomez I; Sánchez-Benavides G; Suárez-Calvet M; Milà-Alomà M; Arenaza-Urquijo EM; Salvadó G; Sala-Vila A; Shekari M; González-de-Echávarri JM; Minguillón C; Niñerola-Baizán A; Perissinotti A; Simon M; Kollmorgen G; Zetterberg H; Blennow K; Gispert JD; Molinuevo JL;
    Alzheimers Res Ther; 2021 Feb; 13(1):46. PubMed ID: 33597012
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Preclinical AD predicts decline in memory and executive functions in subjective complaints.
    van Harten AC; Smits LL; Teunissen CE; Visser PJ; Koene T; Blankenstein MA; Scheltens P; van der Flier WM
    Neurology; 2013 Oct; 81(16):1409-16. PubMed ID: 24049134
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Anti-Correlated Cerebrospinal Fluid Biomarker Trajectories in Preclinical Alzheimer's Disease.
    Gomar JJ; Conejero-Goldberg C; Davies P; Goldberg TE;
    J Alzheimers Dis; 2016; 51(4):1085-97. PubMed ID: 26967213
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Brain metabolic correlates of CSF Tau protein in a large cohort of Alzheimer's disease patients: A CSF and FDG PET study.
    Chiaravalloti A; Barbagallo G; Ricci M; Martorana A; Ursini F; Sannino P; Karalis G; Schillaci O
    Brain Res; 2018 Jan; 1678():116-122. PubMed ID: 29066367
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.